Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy.
Fyhrquist F, Eriksson A, Saijonmaa O, Nordestgaard BG, Kontula K, de Faire U, Ibsen H, Kjeldsen S, Os I, Dahlöf B. Fyhrquist F, et al. Among authors: de faire u. J Renin Angiotensin Aldosterone Syst. 2013 Sep;14(3):227-34. doi: 10.1177/1470320312460292. Epub 2012 Oct 17. J Renin Angiotensin Aldosterone Syst. 2013. PMID: 23077078 Free article.
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group. Fyhrquist F, et al. Among authors: de faire u. Hypertension. 2005 Apr;45(4):580-5. doi: 10.1161/01.HYP.0000161186.55933.6b. Hypertension. 2005. PMID: 15790960
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Wachtell K, et al. Among authors: de faire u. Ann Intern Med. 2003 Dec 2;139(11):901-6. doi: 10.7326/0003-4819-139-11-200312020-00008. Ann Intern Med. 2003. PMID: 14644892 Clinical Trial.
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, Fyhrquist F, Ibsen H, Lindholm LH, Omvik P, Wedel H, Beevers G, de Faire U, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Dahlöf B; LIFE Study Group. Reims HM, et al. Among authors: de faire u. Blood Press. 2004;13(6):376-84. doi: 10.1080/08037050410016483. Blood Press. 2004. PMID: 15771223 Clinical Trial.
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Narayan P, Nieminen MS, Omvik P, Oparil S, Wedel H. Olsen MH, et al. Among authors: de faire u. Am Heart J. 2009 Jan;157(1):177-84. doi: 10.1016/j.ahj.2008.08.011. Epub 2008 Oct 17. Am Heart J. 2009. PMID: 19081416 Clinical Trial.
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, Eliasson E, Fyhrquist F, Hille DA, Ibsen H, Lyle PA, Berg K, Sandberg M, Sethi AA, Wong PH, Os I. Nordestgaard BG, et al. Among authors: de faire u. Pharmacogenet Genomics. 2010 Feb;20(2):77-85. doi: 10.1097/FPC.0b013e328333f70b. Pharmacogenet Genomics. 2010. PMID: 20065889 Clinical Trial.
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y; LIFE substudy. Ibsen H, et al. Among authors: de faire u. J Hypertens. 2004 Sep;22(9):1805-11. doi: 10.1097/00004872-200409000-00026. J Hypertens. 2004. PMID: 15311110 Clinical Trial.
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Kjeldsen SE, Lyle PA, Kizer JR, Dahlöf B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H; LIFE Study Group. Kjeldsen SE, et al. Among authors: de faire u. J Clin Hypertens (Greenwich). 2005 Mar;7(3):152-8. doi: 10.1111/j.1524-6175.2005.04254.x. J Clin Hypertens (Greenwich). 2005. PMID: 15785156 Free PMC article. Clinical Trial.
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB. de Simone G, et al. Among authors: de faire u. Circulation. 2005 Apr 19;111(15):1924-31. doi: 10.1161/01.CIR.0000161799.91577.0A. Circulation. 2005. PMID: 15837945 Clinical Trial.
539 results